Navigation Links
‘2-Hour Patient Acceptance Guarantee’ Program from BioPlus Specialty Pharmacy Rolls Out to Enthusiastic Physician and Patient Response

Altamonte Springs, FL (PRWEB) June 12, 2013

The 2-Hour Patient Acceptance Guarantee program from BioPlus Specialty Pharmacy (BioPlus), one of the nation’s leading specialty pharmacies, streamlines the treatment process for both patients and providers. This program, which launched on April 1, 2013, guarantees notification to physician offices in less than two hours whether their referred patients can be admitted pending insurance qualifications or are non-admitted and triaged to another pharmacy.

“Now that our program is up and running, response from prescribing physicians and patients has been overwhelmingly positive; the benefits to both prescribers and patients was just what we hoped for when we designed this program,” shares Elvin Montanez, Pharm.D., Senior Vice President at BioPlus.

BioPlus raises the bar for the entire specialty pharmacy industry with this program. “BioPlus collapses the wait time for patients and their doctors from days down to a mere two hours. Last week, our internal tracking confirmed how we are saving time for prescribers and patients, with 98 percent of our referrals meeting our two hour guarantee for processing,” says BioPlus’ Senior Director of Admissions, Amanda Brown. “Before we started our 2-Hour program, this sort of turnaround was simply unheard of – we’re proud to be touching lives and encouraging this type of meaningful change for patients,” she adds.

BioPlus pairs this 2-Hour program with a community partnering “Pay It Forward” campaign. For every referral exceeding two hours, BioPlus makes a donation in the physician’s name to a non-profit patient foundation; a smaller donation is still made for every referral processed within the guaranteed time. The non-profit patient foundations benefiting from Pay It Forward include the Patient Access Network (PAN) Foundation, the Chronic Disease Fund, and CancerCare.

“BioPlus is a wonderful supporter of the work we do at Patient Access Network Foundation, both through patient referrals and now through the new Pay it Forward campaign,” says Korab Zuka, Vice President of External Relations & Patient Services at the PAN Foundation. “Through funds donated by the Pay it Forward campaign, PAN will help an even greater number of patients who would otherwise be unable to afford their specialty medications.”

In addition to donating to patient foundations, BioPlus connects patients, as needed, to these foundations through our Patient Foundation Assistance program. Last year, we successfully linked BioPlus patients to $5.1 million in foundation grants and co-pay assistance to help cover their high co-pays and deductibles. BioPlus staff does far more than simply provide patients with the phone numbers for these various foundations; they process the funding foundation paperwork for patients. Each patient also receives continued assistance for grant renewals to ensure uninterrupted treatment.

About BioPlus Specialty Pharmacy

BioPlus is a pharmacist-owned, URAC accredited, national specialty infusion pharmacy providing high-touch services and specialty pharmaceuticals for patients with chronic diseases such as hepatitis, bleeding disorders, immune deficiencies, neuromuscular disorders, cancer, and other conditions. Licensed in all 50 states, BioPlus is one of the nation’s largest independent specialty pharmacies. Accredited by VIPPS, Accreditation Commission for Health Care (ACHC), and the Community Health Accreditation Program (CHAP), patients can contact the Pharmacy toll free at 1-888-514-8082.

For information: or
Contact: info(at)bioplusrx(dot)com
Phone: 1-888-292-0744


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
3. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
4. Study finds doctors have exaggerated fears when starting patients on insulin
5. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
6. Predictors identified for rehospitalization among post-acute stroke patients
7. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Heart failure patients with diabetes may benefit from higher glucose levels
10. Gastro Woes Often Strike Rheumatoid Arthritis Patients
11. Short Walks May Ease Fatigue in Pancreatic Cancer Patients
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: